高血压中的阿提诺洛尔:这是一个明智的选择吗?
Bo Carlberg1, Ola Samuelsson, Lars Hjalmar Lindholm
1Department of Public Health and Clinical Medicine, Umeå University Hospital, SE 901 85 Umeå, Sweden.
Lancet (London, England)
|November 9, 2004
概括
在高血压患者中,与安慰剂相比,阿提诺洛 (β 阻断剂) 并没有改善结局. 然而,它比其他抗高血压药物显示出更高的死亡率和中风风险,质疑其使用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 阿提诺洛尔是用于高血压的广泛使用的β阻塞剂.
- 它作为临床试验中的参考药物的适用性受到质疑.
研究的目的:
- 系统地审查阿提诺洛尔对高血压患者心血管发病率和死亡率的影响.
主要方法:
- 随机对照试验的系统审查和元分析.
- 搜索包括Cochrane图书馆,MEDLINE和专家沟通.
- 包括的试验比较阿诺洛尔与安慰剂或其他抗高血压药物.
主要成果:
- 与安慰剂相比,阿诺洛尔在全因死亡率,心血管死亡率或心肌梗塞中没有显著差异.
- 阿提诺洛尔与降低中风风险的趋势相比于安慰剂有关.
- 与其他抗高血压药物相比,阿诺洛尔的死亡率显著增加,中风频率增加.
结论:
- 作为治疗高血压患者的阿提诺洛尔的疗效和安全性值得怀疑.
- 它作为高血压结局试验中的参考药物的作用应该重新考虑.
相关概念视频
Errors occurring during blood pressure monitoring
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension I: Introduction
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


